maveropepimut-S + cyclophosphamide

Maveropepimut-S + cyclophosphamide is an investigational combination immunotherapy regimen developed by IMV Inc. (in collaboration with BioVaxys Technology Corp.) for the treatment of survivin-expressing malignancies, including recurrent ovarian cancer and diffuse large B-cell lymphoma (DLBCL). Maveropepimut-S (formerly DPX-Survivac) is a peptide-based biologic consisting of five survivin-derived HLA-restricted peptides, a universal T-helper peptide (A16L), and a poly(I:C) adjuvant (polydIdC), all encapsulated within the proprietary DPX lipid-based, non-aqueous delivery platform. This platform facilitates the active uptake of antigens by antigen-presenting cells at the injection site, leading to the generation of a sustained, survivin-specific CD8+ T-cell response. The regimen includes low-dose, intermittent oral cyclophosphamide, which serves as an immunomodulator to enhance the vaccine's efficacy, likely by depleting regulatory T cells and reducing immunosuppression within the tumor microenvironment.

Other names

MVP-S + cyclophosphamideDPX-Survivac + cyclophosphamideMVP-S + CPADPX-Survivac + CPAMVP-S + intermittent low-dose cyclophosphamide